Scientifica Venture Capital selects Hemera among the most innovative deep-tech companies in Italy

Nov 9, 2023 | News

Important Recognition for REMaST® Therapy: A New Perspective for Patients with Spinal Cord Injuries Hemera has been selected among the most innovative science-based entrepreneurial initiatives in Italy by the investment holding Scientifica Venture Capital, which...

Hemera Pharma: Excellence and Innovation Recognized with Women Startup Award in Regenerative Medicine

Sep 29, 2023 | News

Hemera Pharma Receives Women Startup Award for Excellence in Regenerative Medicine We are delighted to share Hemera Pharma’s recent achievements in the field of regenerative medicine. On September 29, amidst the prestigious setting of OGR Torino, Hemera Pharma...

Cristiana Vignoli, CEO of Hemera, among the Top 7 Innovative Entrepreneurs at the GammaDonna Award 2023.

Sep 4, 2023 | News

Cristiana Vignoli, CEO of Hemera, among the Top 7 Innovative Women Entrepreneurs at the GammaDonna Award 2023 We are proud to share an extraordinary milestone for Hemera: our CEO, Cristiana Vignoli, has been selected for the #FAB50 shortlist of the 2023 GammaDonna...

Hemera Pharma among the 50 most innovative companies of the 2023 “Premio Gamma Donna”

Jun 22, 2023 | Events, News

Cristiana Vignoli in the shortlist of the FAB50, the 50 most innovative female entrepreneurs of the “PremiO Gamma Donna” We are pleased to announce that our Chief Executive Officer Cristiana Vignoli has been included in the prestigious FAB50 short list of...

Hemera receives Orphan Drug Designation for REMaST® therapy

Jun 8, 2023 | News

REMaST® recognized as an orphan drug for acute spinal injuries The advanced cell therapy REMaST® developed by Hemera has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...

Hemera Receives Orphan Drug Designation for REMaST® Therapy

Jun 8, 2023 | News, Press Releases

REMaST® Recognized as an Orphan Drug for Acute Spinal Cord Injuries The advanced cell therapy REMaST®, developed by Hemera, has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...